SCHEMBL8221499

SCHEMBL8221499

Nc1nc2ccccc2c2nn(Cc3ccc(Cl)cc3Cl)c(=O)n12

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPSR1 Q6W5P4 2/20 0.48
▸ CYP1A2 P05177 1/20 0.48
▸ CYP3A4 P08684 1/20 0.48
▸ CYP2D6 P10635 1/20 0.48
▸ CYP2C9 P11712 1/20 0.48
▸ TSHR P16473 1/20 0.48
▸ PMP22 Q01453 1/20 0.48
▸ HIF1A Q16665 1/20 0.48
▸ ADORA2A P29274 9/20 0.46
▸ SLC9A1 P19634 1/20 0.46
▸ ADORA1 P30542 2/20 0.44
▸ ALDH1A1 P00352 2/20 0.44
▸ KDM4E B2RXH2 1/20 0.44
▸ GLA P06280 1/20 0.44
▸ HPGD P15428 1/20 0.44
▸ VDR P11473 1/20 0.42
▸ LMNA P02545 3/20 0.41
▸ HTT P42858 2/20 0.41
▸ SMN1; SMN2 Q16637 2/20 0.41
▸ MAPT P10636 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8220814 0.91 ADORA2A (0.46) NPSR1CYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL13341575 0.89 NPSR1 (0.50) NPSR1CYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL8224740 0.89 TNF (0.51) NPSR1CYP1A2CYP3A4CYP2C9ADORA2A
SCHEMBL8221012 0.88 ADORA2A (0.46) ADORA2AADORA1
SCHEMBL8221845 0.85 ADORA2A (0.55) NPSR1CYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL8224052 0.85 ADORA2A (0.43) ADORA2AADORA1
SCHEMBL8221183 0.83 ADORA2A (0.47) CYP1A2CYP3A4CYP2C9ADORA2AADORA1
SCHEMBL8223855 0.83 ADORA2A (0.64) ADORA2AADORA1MAPT
SCHEMBL8223871 0.83 ADORA2A (0.53) ADORA2AADORA1
SCHEMBL8221822 0.82 ADORA2A (0.63) ADORA2AADORA1ALDH1A1LMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7713985-B2 Adenosine Aa2 receptor antagonists SCHERING CORPORATION (US) 2010-05-11 — — US disclosed
US-7713985-B2 Adenosine Aa2 receptor antagonists SCHERING CORPORATION (US) 2010-05-11 — — US disclosed
US-20080255156-A1 ADENOSINE A2A RECEPTOR ANTAGONISTS MERCK SHARP & DOHME LLC 2008-10-16 — — US disclosed
US-20080255156-A1 ADENOSINE A2A RECEPTOR ANTAGONISTS MERCK SHARP & DOHME LLC 2008-10-16 — — US disclosed
WO-2008002596-A2 ADENOSINE A2A RECEPTOR ANTAGONISTS SCHERING CORPORATION (US) 2008-01-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080255156-A1 ADENOSINE A2A RECEPTOR ANTAGONISTS ADORA3, ADORA2A, ADORA1 NPSR1 157/4885CYP1A2 1308/4885CYP3A4 1749/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback